Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhancing Immunogenicity in NRAS-Mutant Melanoma Via Autophagy Modulation
NCT07750067Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine, tunlametinib, pucotenlimab in melanoma, sponsored by Sun Yat-sen University. Started Apr 2026; status: recruiting.
02
Drugs
hydroxychloroquinetunlametinibpucotenlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07750067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750067.